Trevi Therapeutics, Inc. (TRVI) - Form 8-K Summary
Business Context and Reporting Period
Trevi Therapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on March 17, 2026. The filing announces the Company's financial results for the quarter and full year ended December 31, 2025. The Company's common stock trades on The Nasdaq Stock Market LLC under the symbol TRVI.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report serves as a notification that these results have been announced and directs readers to the press release furnished as Exhibit 99.1 for detailed figures.
Material Changes
No specific material changes versus the prior comparable period are detailed within the text of this Form 8-K. The document references the full press release for the complete financial performance analysis.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors in its body text. It explicitly states that the information under Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and FY 2025.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the accompanying press release.
- Confirm the status of any outstanding debt or financing arrangements referenced in the detailed financial statements.